Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

ACUROX(R) and EMBEDA (TM) Data Highlighted at the College on Problems of Drug Dependence Annual Meeting

RENO, Nev., June 25 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) today announced that the Company is presenting safety and efficacy data for ACUROX(R) and EMBEDA(TM) (ALO-01), two novel opioid analgesic formulations that are in development, at the 71st Annual Meeting of the College on Problems of Drug Dependence. King is also developing other pain medicines employing unique technology platforms designed to address risks associated with currently marketed opioids.

"We anticipate that ACUROX(R) and EMBEDA(TM), upon approval, will offer new therapeutic tools for physicians treating people living with pain," said Eric Carter, Chief Science Officer of King Pharmaceuticals. "Our expectation is that these novel technologies could become instrumental in a physician's arsenal of safe and effective pain medicines that can help with an overall risk management plan."

Highlights of King's presentations and King supported presentations are as follows:

ACUROX(R) (oxycodone HCl/niacin) Tablets for the Treatment of Acute, Moderate to Severe Pain Following Bunionectomy Surgery in Adult Patients

ACUROX(R) Tablets are a unique composition of short-acting oxycodone HCl, niacin and functional inactive ingredients intended to relieve moderate to severe pain. A Phase III study evaluated the analgesic efficacy and safety of ACUROX(R) in adults with moderate to severe pain following bunionectomy surgery. The 405 participants received either two ACUROX(R) Tablets 7.5/30 mg, two ACUROX(R) Tablets 5/30 mg or two placebo tablets every six hours for 48 hours after surgery. Both doses of ACUROX(R) Tablets demonstrated significant reduction in pain compared to placebo. The adv
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...RNewswire-FirstCall/--WoundManagementTechnologies,...rofspecialtymedicalproducts,announcedthatithasfile...ivemanagementbusinessupdatetoillustratethedevelopm...ncreased33.5%to$102,926vs.Q32008salesof$77,084. ,...27,892vs.Q32008shareholderequityof$(321,257) ,...
(Date:11/23/2009)...re-FirstCall/--CordBloodAmerica,Inc.(OTCBulletinBo...ncompany( http://www.cordblood-america.com )focuse...ogicalinsurancepolicy,tofamiliesnationwideandinter...rviewwithCEOandco-founderMatthewSchisslerisnowavai...v/file/2875811 . ,, Intheinterview,Mr.Schissler...
(Date:11/23/2009)...ewswire-FirstCall/--RaptorPharmaceuticalCorp.("Rap...epresentationofclinicaltrialdataonNGX426,theCompan...torantagonist,atthe12thInternationalConferenceonth...ember20-21inSanFrancisco.Theresultsofthestudyledby...attheCenterforPainMedicineoftheUniversityofCalifor...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5Stop and smell the flowers the scent really can soothe stress 9324 1New windows opened on cell to cell interactions 9320 1New windows opened on cell to cell interactions 9320 2New windows opened on cell to cell interactions 9320 3Symphony Medical Changes Name to CardioPolymers Inc 13152 1Symphony Medical Changes Name to CardioPolymers Inc 13152 2
...y Identifies Novel Biomarkers Displaying 90% Sensi...ncer -, ST. LOUIS, Dec. 20 Orion Genomics announ... frequent DNA alterations detected in,breast cance...f DNA,methylation appeared in PLoS ONE. The study ...DNA Methylation Changes in Breast Cancer" found mo...
...al Psoriasis Foundation urges psoriasis patients t...re, PORTLAND, Ore., Dec. 19 A study released,thi...re likely to have a,shorter life expectancy should...l health, according to the National Psoriasis Foun...f Dermatology and conducted by,Joel M. Gelfand, M....
Other Medicine Technology:Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers 2Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 2Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 3
(Date:11/24/2009)... Dr. Tom Lintner is embracing the latest ... and keep an ongoing dialogue with patients. Throu...ts, Dr. Lintner provides information about his At...r any questions that patients may have. , ...2009 -- A plastic surgeon in Atlanta is taking f...
(Date:11/24/2009)... NCL Security Launches EyeCentral Remote ...te Recurring Monthly Revenue for Central Stations ...allas, Texas (PRWEB) November 24, 2009 -- NCL Secu... the Security Industry to Generate Recurring Month...rs., , ,"Integrated security systems has been...
(Date:11/23/2009)...olomics study by researchers from Virginia Commonw...that impaired peroxisomal oxidation of polyunsatur...gression of nonalcoholic fatty liver (NAFL) to non... found significantly higher plasma monounsaturated...d NASH. Full findings appear in the December issu...
(Date:11/23/2009)... After suffering from women,s hair loss f...wing back and she,s sharing her progress and the s...omen through the release of her video diaries whic...nd during her treatment. , ...loss sufferer Zsanett Siklosi has released the vi...
(Date:11/23/2009)...ontinuetoTargetIndividualsintheRecommendedPriority...Newswire/--TheDepartmentofHealthannouncedtodaythey...localStateHealthCentersinDelaware,Lancaster,andLeh...eH1N1vaccinewillbeadministeredforfreetoindividuals...accesstothevaccine.Thedepartmentasksthatonlyindivi...
Breaking Medicine News(10 mins):Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 2Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 3Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2
...e-owned Hindustan Latex Ltd., will be launched nex...e past year we had test marketed 30,000 pieces of ...ellent response from both men and women, we have d...ctor of the company, told reporters here Thursday....
...have financed the bypass surgery of a fisherwoman ... Thanks to their efforts, B. Hemavati, 35, wi...o a life saving operation at the Tirupati-based Sr...ent that doctors said would cost up to Rs.90,000 w...
...bal supplement can effectively combat cocaine addi...which is a potential agent to modulate the effects...y tried in animal models for the treatment of hero...re agents that clean up damaging free radicals in ...
...omputerized tomography (CBCT) is increasingly beco...cated oral problems.// J. Martin Palomo and Ma... Case Western Reserve University School of Dental ...e published an article in the current issue of the...
...m Gladstone Institute of Neurological Disease have... responsible for causing Alzheimer's disease //tha...nto energy in Mitochondirial cells due to the prot...nt in the brain to the neurons causing brain cell ...
...y the Oregon National Primate Research Center at O...hers, which appears to control stem cells becoming...red for conditions like Parkinson's disease and br...lls in later stages. The glial cells perfor...
Other Medicine News:Health News:Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each 2Health News:A herbal drug addiction releiver 2Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2
...pping System combines the legendary accuracy of th... software. It integrates seamlessly into your EP ...e your clinical capabilities in an easy-to-upgrade...he intended use of the CARTO XP System is catheter...
Model 3077 Single-Chamber Temporary Pacemaker
...'s broadest line of endocardial temporary pacing c...able in both torque control and flow-directed mode...ode spacing options. The Pacel Bipolar Pacing Cat...us right ventricular pacing. Prophylactic system...
Novacor LVAS
Medicine Products: